Showing results (141-150 of 217) with videos related to

Sort By:
Pageof 22
Eclinicalmedicine|October 23, 2025
AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective studyGuanchao Ye, Zhitao Wei, Chu Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2026
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology SubcommitteeRyan A McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2025
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumabFrancesco Cortiula, Talia Shentzer Kutiel, Melinda L Hsu, et al.
JAMA Network Open|February 3, 2026
Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-AnalysisJonas Willmann, Camilla von Wachter, Ronja Zehnder, et al.
BMC Cancer|September 1, 2022
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey studyNaomi C A van der Velden, Hanneke W M van Laarhoven, Sjaak A Burgers, et al.
Targeted Oncology|June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose OsimertinibFenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicityRob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
The Oncologist|May 9, 2023
Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced CancerNaomi Cornelia Anna van der Velden, Paul K J Han, Hanneke W M van Laarhoven, et al.
Pageof 22